



# Ligustrazine Hydrochloride Datasheet

5<sup>th</sup> Edition (Revised in January, 2017)

## [ Product Information ]

**Name:** Ligustrazine Hydrochloride

**Catalog No.:** CFN99910

**Cas No.:** 76494-51-4


**Purity:** >=98%

**M.F:** C<sub>8</sub>H<sub>12</sub>N<sub>2</sub>.HCl

**M.W:** 208.69

**Physical Description:** White powder

**Synonyms:** 2,3,5,6-Tetramethylpyrazine hydrochloride; Pyrazine, tetramethyl-, hydrochloride.



## [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

## [ Source ]

The rhizomes of *Ligusticum chuanxiong* Hort.

## [ Biological Activity or Inhibitors ]

Ligustrazine Hydrochloride has certain protection effect on the vascular endothelium undergoing cardiopulmonary bypass (CPB), and lower excessive activation of coagulation reaction and inflammation reaction in patients undergoing CPB.<sup>[1]</sup>

Ligustrazine hydrochloride can inhibit the activation of human platelet following severe brain injury, improve the balance of TXA<sub>2</sub> - PGI<sub>2</sub> within the circulatory blood, suggests that it may be used as one of the agents to treat brain injury.<sup>[2]</sup>

Ligustrazine Hydrochloride can exert down-regulate effects on Colon26 secretion of immunosuppressors and its tumor immunosuppression, one of the mechanisms is reducing tumor immunosuppression of Colon26 through decreasing its secretion of immunosuppressors.<sup>[3]</sup>

Ligustrazine hydrochloride injection has antithrombotic effect on the model of induced arteriovenous shunt thrombosis.<sup>[4]</sup>

## **[ Solvent ]**

Pyridine, Methanol, Ethanol, etc.

## **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: Methanol-1% Aqueous acetic acid=46:54;

Flow rate: 1.0 ml/min;

Column temperature: 30 °C;

The wave length of determination: 293 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Chen Y J. *Zhongguo Zhong xi yi jie he za zhi*, 2014, 34(5):531-5.

[2] Chen J L, Chen Z M, Yang Y J, et al. *Chinese Journal of Nervous & Mental Diseases*,

1994,20(3):151-4.

[3] Cui C, Wang R T, Zhang Y H, *et al.* *Chinese Journal of Immunology*, 2009, 25(5):413-6.

[4] Wang P, Luo C H, Wang Q X, *et al.* *J. Res. Med. Sci.*,2013,18(8):704-6.

[5] He X P, Wang X Y. *China Pharmacy*, 2016(9):1270-1.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)